Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577356 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
A Phase 2 study, sponsored by Benaroya Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00577356 is a Phase 2 study that was terminated before completion, run by Benaroya Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT00577356, a Phase 2 study, was terminated before completion, sponsored by Benaroya Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).
Interventions
- DRUG Docetaxel
- BIOLOGICAL CG1940/CG8711
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577356
The ClinicalTrials.gov registry entry for NCT00577356 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00577356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577356 about?
NCT00577356 is a clinical study titled "Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer". The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).
What is the current status of trial NCT00577356?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00577356?
The interventions under investigation include: Docetaxel (DRUG), CG1940/CG8711 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00577356?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.